Get the Stockscreener App
0.5819
0.52%
-0.0091
Lyell Immunopharma Inc stock is traded at $0.5819, with a volume of 276.36K.
It is down -0.52% in the last 24 hours and down -11.39% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$0.591
Open:
$0.5977
24h Volume:
276.36K
Relative Volume:
0.23
Market Cap:
$172.67M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-0.7366
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
-0.41%
1M Performance:
-11.39%
6M Performance:
-58.30%
1Y Performance:
-66.60%
1-Day Range:
$0.5793
$0.6049
1-Week Range:
$0.57
$0.6355
52-Week Range:
$0.5505
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.585 | 172.67M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
717.55 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.40 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.24 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.86 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma Inc (LYEL) Stock: A Year of Market Fluctuations - The InvestChronicle
Take off with Lyell Immunopharma Inc (LYEL): Get ready for trading - SETE News
LYEL underperforms with a -0.98 decrease in share price - US Post News
Market Momentum Report: Lyell Immunopharma Inc (LYEL)’s Negative Close at 0.58 - The Dwinnex
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma price target lowered to 60c from $1 at BofA - MSN
Lyell Immunopharma stock hits 52-week low at $0.58 - Investing.com India
Lyell to Highlight Vision for its Next-Generation CAR - GlobeNewswire
Lyell's IMPT-314 Cancer Therapy Shows 94% Response Rate, Plans Pivotal Trials for Lymphoma - StockTitan
Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Barclays PLC Has $332,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
State Street Corp Has $5.37 Million Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell' - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLC - Defense World
Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance
Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan
Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire
Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com
Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow
Lyell Immunopharma Reports Resignation of Board Member - Defense World
Lyell Immunopharma Director Hans bishop resigns - Investing.com
Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - The Manila Times
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):